Immunitas Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 18 employees on LinkedIn · 9 known investors
Find your way into Immunitas Therapeutics
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
Founders & leadership
AW
Amanda WagnerNamed on SEC filing
DM
Dan MatloffNamed on SEC filing
JG
Jiaping GuNamed on SEC filing
JG
Jeffrey GoldbergNamed on SEC filing
Board
LB
KW
JE
Juergen EckhardtBoard director
CW
LI
Investors · 9
Agent CapitalWaltham
DC Investment PartnersMcLean · $10M
Longwood FundBostonvia Christoph Westphal · board
Medical Excellence CapitalNew York
Novartis Venture FundBasel · $5M – $25M
Ono Venture Investment, Inc.South San Francisco
Solasta VenturesBoston
Leaps by BayerreportedLeverkusen
M Venturesreported · 2 sourcesLos Angeles · $10.8M
Reported raises · per SEC filings
Form D private placements$29.1M disclosed across 1 round · 2021
▶$29.1MraisedAug 2021 · 21 investors · BiotechnologyRule 506(b)
▶$29.1MraisedAug 2021 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laura BrassDirector
- Amanda WagnerExecutive Officer
- Kai WucherpfennigDirector
- Dan MatloffExecutive Officer
- Jiaping GuDirector
- Jeffrey GoldbergExecutive Officer, Director
- Juergen EckhardtDirector
- Christoph WestphalDirector
- Lucio IannoneDirector
- Offering amount
- $57.7M
- Amount sold
- $29.1M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBioworld25 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Immunomic Therapeutics21 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Inimmune19 shared keywordsInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Solu19 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Immunitas Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Immunitas Therapeutics do?
- Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
- Who are Immunitas Therapeutics's investors?
- Immunitas Therapeutics's investors include Agent Capital, DC Investment Partners, Longwood Fund, Medical Excellence Capital, Novartis Venture Fund, Ono Venture Investment, Inc., Solasta Ventures, Leaps by Bayer and 1 more.
- How much funding has Immunitas Therapeutics raised?
- Immunitas Therapeutics has disclosed $29.1M raised across 1 round.
- Where is Immunitas Therapeutics headquartered?
- Immunitas Therapeutics is headquartered in Waltham, US.